Holen Sie sich die Stockscreener-App
34.84
2.71%
0.92
Handel nachbörslich:
34.16
-0.68
-1.95%
Schlusskurs vom Vortag:
$33.92
Offen:
$33.98
24-Stunden-Volumen:
623.09K
Relative Volume:
0.92
Marktkapitalisierung:
$2.70B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-170.19M
KGV:
-11.42
EPS:
-3.0495
Netto-Cashflow:
$-154.68M
1W Leistung:
+5.77%
1M Leistung:
+6.22%
6M Leistung:
+119.26%
1J Leistung:
+49.72%
1-Tages-Spanne:
$33.59
$34.92
1-Wochen-Bereich:
$32.35
$35.58
52-Wochen-Spanne:
$10.91
$35.58
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
34.84 | 2.63B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
How does Spyre Therapeutics Inc score in quality rankingsGDP Growth & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Spyre Therapeutics, Inc. $SYRE Shares Acquired by Candriam S.C.A. - MarketBeat
Risks Report: Is Spyre Therapeutics Inc. benefiting from interest rate changesJuly 2025 Update & Accurate Trade Setup Notifications - mfd.ru
Aug Final Week: Is Spyre Therapeutics Inc stock a hidden gemJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - baoquankhu1.vn
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighHere's What Happened - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Short Interest in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Drops By 13.5% - Defense World
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock - MarketBeat
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Turtle Cameron, Spyre Therapeutics CEO, sells shares worth $492k By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Sees Significant Decrease in Short Interest - MarketBeat
AlphaQuest LLC Purchases 61,989 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
VIX Spike: Is SOUNW a cyclical or defensive stockJuly 2025 Macro Moves & Weekly High Potential Stock Alerts - baoquankhu1.vn
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Biotechnology Innovator with 68% Upside Potential - DirectorsTalk Interviews
Nasdaq Moves: How does Spyre Therapeutics Inc score in quality rankingsCEO Change & Smart Swing Trading Techniques - baoquankhu1.vn
Trend Review: Is Spyre Therapeutics Incs ROIC above industry averagePrice Action & Weekly Top Performers Watchlists - baoquankhu1.vn
Is Spyre Therapeutics Incs ROIC above industry averageJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
Spyre’s new commercial chief granted 108K stock options at $34.09 - Stock Titan
Insider Buy: Can SYFPRA maintain sales growthAnalyst Upgrade & AI Forecast Swing Trade Picks - baoquankhu1.vn
Bull Run: Can Spyre Therapeutics Inc lead its sector in growth2025 Geopolitical Influence & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Aug Final Week: Is FORL a defensive stockChart Signals & Accurate Trade Setup Notifications - baoquankhu1.vn
Big Picture: How does Spyre Therapeutics Inc score in quality rankings2025 Price Action Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development - MSN
Wall Street bullish on Spyre Therapeutics, Inc. (SYRE) with strong buy rating - MSN
Weekly Trades: Is FNGSs growth already priced inTrend Reversal & Growth Focused Entry Point Reports - baoquankhu1.vn
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance - Yahoo Finance
SYRE: BTIG Reiterates Buy Rating with $70 Price Target | SYRE St - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research - MarketBeat
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Insider Monkey
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% HigherWhat's Next? - MarketBeat
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments By Investing.com - Investing.com Nigeria
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072 - MSN
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments - Investing.com
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership - TipRanks
Quarterly Risk: Is Spyre Therapeutics Inc a top pick in the sectorMarket Activity Summary & High Conviction Trade Alerts - baoquankhu1.vn
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts - TradingView — Track All Markets
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - The Manila Times
Spyre Therapeutics IncSkyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule - TradingView
Six drug trials target colitis and arthritis, with first patient data in 2026 - Stock Titan
Spyre Therapeutics' CEO Sells 15,000 Shares - The Motley Fool
What technical charts say about OXYWS stockJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Sentiment Recap: Is Spyre Therapeutics Inc. stock cheap at current valuation2025 Pullback Review & Smart Investment Allocation Insights - Улправда
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Innovative Biotech with 86.51% Upside Potential - DirectorsTalk Interviews
Why Spyre Therapeutics Inc. stock is popular among millennials2025 Geopolitical Influence & Technical Entry and Exit Tips - Улправда
Why Spyre Therapeutics Inc. stock remains resilient2025 Market Overview & Verified Entry Point Detection - Улправда
Is Spyre Therapeutics Inc. stock a contrarian buy2025 Pullback Review & Entry and Exit Point Strategies - Улправда
Is Spyre Therapeutics Inc. stock positioned for digital transformationPortfolio Profit Report & Capital Efficient Trading Techniques - Улправда
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Brokerages - Defense World
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):